Please login to the form below

Not currently logged in


This page shows the latest risankizumab news and features for those working in and with pharma, biotech and healthcare.

FDA clears Lilly’s Taltz for ankylosing spondylitis

FDA clears Lilly’s Taltz for ankylosing spondylitis

Meanwhile, the new approval also keeps Taltz ahead of some other new competitors, particularly AbbVie/Boehringer Ingelheim’s new IL-23 inhibitor Skyrizi (risankizumab) which AbbVie thinks can become a $5bn

Latest news

More from news
Approximately 3 fully matching, plus 17 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company
Six Degrees Medical Consulting

For over a decade, our medical communication services have helped pharmaceutical companies optimize their brand, disease and corporate objectives. Building...

Latest intelligence

Article: Like, Like, Like: Harnessing the power of social media insights
Its Know Your Numbers week
Do you know yours?...
What is changing in mental health and dementia care?
Paul Midgley, of Wilmington Healthcare, takes a look at the NHS Long Term Plan's bid to transform mental health and dementia services...